Home Tags Gene editing
Tag: gene editing
We’ll be eating the first Crispr’d foods within 5 years, according to a geneticist who helped invent the blockbuster gene-editing tool
A UC Berkeley geneticist who helped invent the gene-editing tool Crispr told Business Insider its most profound impacts will be on agriculture.
Scientists have successfully created the world's first gene-edited reptile — an albino lizard no bigger than a finger.
Dispensed: Change at the FDA, insurance startup financials for 2018, and the first new depression drug in 35 years
Welcome to Dispensed, Business Insider's weekly newsletter giving you a dose of pharma, biotech, and healthcare news.
The Chinese scientist who claims to have edited baby DNA is downplaying reports that he is under house arrest. Here’s a timeline of the controve...
He Jiankui told other scientists he is doing well, downplaying reports that he is being held in a guesthouse against his will, STAT reported.
Bill Gates warns that nobody is paying attention to gene editing, a new technology that could make inequality even worse
Bill Gates, the billionaire philanthropist, recently described gene editing as "the most important public debate we haven't been having widely enough."
Akouos, a biotech startup that’s trying to tackle a $750 billion global problem, just announced it’s raised a new funding round
Akouos, the first biotech startup that's taking a precision medicine approach to hearing loss, announced a $50 million Series A funding round on Tuesday.
Headlines linking blockbuster gene-editing tool CRISPR to cancer sent stocks in companies trying to bring the technology to medicine tumbling. But scientists who study the technique say the concerns are overblown at best, and an incorrect interpretation of the science at worst.
A troubling link has been found between a cutting-edge gene-editing technology and cancer — and it’s sending biotech stocks tumbling
In new studies published Monday in the journal Nature Medicine, CRISPR-Cas9 was found to increase risk of cancer due to its disruption of the p53 protein.
The German drugmaker and chemical company Bayer has finalized a $66 billion blockbuster deal to gobble up the agricultural behemoth Monsanto, but you wouldn't know it by the company's new name. On Monday, Bayer said it was dropping Monsanto's 117-year-old title.
The FDA just put a pause on a cutting-edge gene editing trial that hadn’t started yet — and the company’s stock is dropping
The trial, run by CRISPR Therapeutics and Vertex Pharmaceuticals, plans to look at how the gene-editing technology works to treat patients with sickle cell disease. The trial has been put on hold "pending the resolution of certain questions that will be provided by the FDA."